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Abstract: Dehydroepiandrosterone (DHEA) is the most abundant steroid hormone in the 
circulation and has potent multifunctional activity. Epidemiological evidence suggests that 
levels of serum DHEA decrease with advancing age, and this has been associated with onset 
or progression of various age-related ailments, including cognitive decline and dementia, car-
diovascular disease, and obesity. Consequently, these findings have sparked intense research 
interest in DHEA supplementation as an “antiaging” therapy. Currently, DHEA is being used by 
25% of in vitro fertilization (IVF) clinicians as an adjuvant in assisted reproductive programs, 
yet the therapeutic benefit of DHEA is unclear. Here, we examined the use of novel DHEA-
containing oral troches in patients undertaking IVF and investigated the impact of these troches 
on their serum androgen profile. This retrospective study determined the androgen profile of 
31 IVF patients before (baseline) and after DHEA supplementation (with DHEA). Baseline 
serum measurements of testosterone (total and free), DHEA sulfate (DHEAS), sex hormone-
binding globulin (SHBG), and androstenedione were made before and after supplementation. 
Each patient received DHEA troches containing 25 mg of micronized DHEA, and troches 
were administered sublingually twice daily for a period of no greater than 4 months. Adjuvant 
treatment with DHEA boosted the serum concentration of a number of androgen-related ana-
lytes, including total and free testosterone, androstenedione, and DHEAS, while serum SHBG 
remained unchanged. Supplementation also significantly increased the free-androgen index 
in IVF patients. Interestingly, the increase in serum analyte concentration following DHEA 
supplementation was found to be dependent on body mass index (BMI), but not individual age. 
Patients with the lowest BMI (,20.0 kg/m2) tended to have lower testosterone and DHEAS, 
but higher SHBG and androstenedione levels in comparison with other BMI groups postsupple-
mentation. However, patients in the highest BMI group (.30.0 kg/m2) tended to have lower 
androgen responses following DHEA supplementation, but these were not statistically different 
from the corresponding baseline level. This method of DHEA administration results in a similar 
enhancement of testosterone, DHEAS, and androstenedione levels in comparison with other 
methods of administration. Furthermore, we showed that BMI significantly influences DHEA 
uptake and metabolism, and that BMI should be carefully considered during dosage calculation 
to ensure a significant and robust androgen-profile boost.
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Introduction
Dehydroepiandrosterone (DHEA) is a multifunctional adrenal prohormone that has 
potent biological activity. It is the most abundant steroid hormone in the circulation, 
but natural serum concentrations depend on individual age and sex.1 DHEA can directly 
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elicit its effects through interaction with receptors located in 
the plasma membrane, cytoplasm, and nuclear membrane, 
which ultimately translocate inside the nucleus, where they 
regulate gene expression.1,2 It has been reported that DHEA 
is a potent ERβ agonist,3 but a weak AR agonist. Although 
DHEA is known to associate with other important cell-
signaling and metabolic receptors, such as PPARγ, a specific 
DHEA receptor has not yet been identified.2 Conversely, some 
earlier studies have indicated that DHEA can bind membrane-
bound protein complexes that may relay DHEA-induced 
processes.4 However, DHEA primarily indirectly stimulates 
various downstream biological responses, by functioning as 
a precursor for the synthesis of powerful sex-steroid hor-
mones (intracrinology), including testosterone and estradiol.1 
Therefore, DHEA supplementation is believed to offer several 
advantages over testosterone administration, due to direct 
albeit weak effects on the AR and as a precursor for other 
androgens, which ultimately results in androgen synthesis 
when required, rather than flooding biological systems directly 
with active androgens, which could cause side effects.5
Metabolic production of DHEA occurs from the substrate 
17-hydroxypregnenolone, under the action of the cytochrome 
P450c17, which is highly expressed in the adrenal glands.1,6 
In downstream peripheral tissues, DHEA can be converted 
to androstenedione and subsequently testosterone by the 
action of 3β-HSD and 17β-HSD, respectively.1 Alternatively, 
DHEA-derived androstenedione can be converted to estrogen 
via P450 aromatase activity, demonstrating an important role 
for DHEA in hormone production for both sexes. DHEA 
mainly circulates in the vasculature as an inactivated sul-
fated derivative (DHEAS).7 A balance exists between these 
DHEA structures, and the interconversion between the two is 
dependent on sulfotransferase and steroid sulfatase enzyme 
activity in peripheral tissues. Since DHEAS is the major form 
of DHEA present in the circulation (typically 10 μM DHEAS 
to 30 nM DHEA),8,9 DHEAS is routinely quantified in the 
clinic as an indirect measure of DHEA status.
Epidemiological evidence suggests that levels of 
serum DHEA/DHEAS decrease with advancing age,10 
and reduced concentrations have been associated with 
onset or progression of various age-related ailments, 
including cognitive decline and dementia,11,12 cardio-
vascular disease,13 cancer,14 obesity,15 and autoimmune 
disease.1,16 However, in many of these fields of research, 
the precise role of DHEA in mediating disease is not clear, 
and in most cases, the literature also demonstrates opposite 
and inconsistent relationships, which further complicates 
the function of DHEA.13,14,17,18 Nonetheless, these studies 
and others have sparked intense research interest in DHEA 
supplementation as an “antiaging” therapy, but DHEA use 
remains controversial.7,8
Within the assisted reproductive technology field, eg, 
in vitro fertilization (IVF), the primary cause of reduced 
success rates is increasing female age. Interestingly, this is 
closely associated with an age-induced reduction of ovarian 
reserve, a measure of reproductive potential of the ovary. In 
Western cultures, there is an increasing propensity of females 
to delay childbirth as a result of socioeconomic factors, 
particularly in relation to extended education and dedication 
to careers, which is unfavorable for their ovarian reserve. 
Furthermore, female androgen levels are vastly lower than in 
the male (as a component part of sex phenotypic differences), 
but good biological androgenic function is thought to be 
required for successful reproduction, as these hormones are 
believed to modulate ovarian physiology, including oocyte 
and follicle maturation, receptor expression, DNA repair, 
mitochondrial function, and the induction of local effects 
on the endometrium during ovulation and implantation.19–22 
Consequently, these findings have led to the recent use of 
DHEA as an adjuvant in assisted reproductive technology 
programs,22 particularly for older patients, who may have 
reduced androgen levels or are categorized as poor ovarian 
responders according to the Bologna criteria.23 However, 
although there is some evidence to indicate improvement in 
IVF success rates with DHEA,24–28 its use remains contro-
versial, and several clinical trials and meta-analyses have so 
far failed to reveal convincingly any true therapeutic benefit 
of DHEA adjuvant treatment in IVF cycles.19,22,29 This is due 
to inconsistent results describing outcomes, due to small or 
poorly designed trials that are self-controlled.
Most of the DHEA adjuvant treatments used in IVF have 
utilized oral (tablet) routes of DHEA administration.25,27,29,30 
Herein, we describe the unique concept of supplementing 
female IVF patients with novel, lipid-based DHEA-containing 
oral sublingual troches to bypass first-pass metabolism, as 
DHEA is highly metabolized and inactivated by the liver. To the 
best of our knowledge, this is the first study of its kind to report 
the administration of DHEA via oral troches, and the first report 
demonstrating an increase in the androgenic profile in response 
to DHEA therapy for female patients undergoing IVF.
Materials and methods
DHEA troche manufacture
DHEA troches were prepared according to an in-house 
recipe. Briefly, DHEA microparticles were dispersed in a 
sweetened and flavored mix of polyethylene glycol base 
(48–105 μM). This mix allows DHEA to release slowly and 
uniformly sublingually. This in turn allows better absorption 
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of DHEA through the buccal route. There were 30 troches 
per preparation tray (Figure 1), with each troche containing 
50 mg DHEA. Each troche was cross-scored, enabling an easy 
cut to provide 25 mg per half, or even 12.5 mg per quarter.
Patients and troche administration
This was a retrospective study (January 2012 to April 2014) 
examining the serum androgen profile of 31 poor-prognosis 
IVF female patients before (baseline) and after DHEA 
supplementation, using novel DHEA-containing oral tro-
ches designed by our group. Patients were not assigned 
to any other adjuvant treatment during this period. Serum 
measurements of testosterone (total and free), DHEAS, sex 
hormone-binding globulin (SHBG), and androstenedione 
were made before (baseline) and 4 weeks after supplementa-
tion (treated). For supplementation, each patient utilized half 
a DHEA troche containing 25 mg of micronized DHEA sub-
lingually twice daily for a period of 6 weeks to a maximum 
of 4 months. At the fourth-week review, only one patient 
in this series had a troche reduction to 12.5 mg because of 
an excess testosterone level; two others reported mild acne, 
which did not require changes in DHEA administration. As a 
comparative control, the androgen profile of patients of simi-
lar age (Figure 2A) and body mass index (BMI; Figure 2B) 
were also assessed on two separate occasions to determine 
spontaneous change in hormone levels (Figure 3). In these 
patients, the second measurement (measurement 2) was made 
on average 50±3 weeks (standard error of mean) following 
the initial androgen-profile screen (Figure 3).
androgen assays
Analysis of serum testosterone, SHBG, and DHEAS was per-
formed using a Cobas 8000 modular analyzer (Hoffman-La 
Roche Ltd, Basel, Switzerland) with coefficients of variation 
of less than 3.14%, 2.23%, and 3.06%, respectively. Analysis 
of serum androstenedione was performed using the Immulite 
2000 immunoassay system (Siemens AG, Berlin, Germany) 
with a coefficient of variation of less than 5.23%. Error bars 
represent ± standard error of mean.
statistical analysis
Statistical analysis of the data was undertaken using Graph-
Pad Prism version 6.0 (GraphPad Software Inc., La Jolla, 
CA, USA). Multiple comparisons were made for each 
measured variable using one-way analysis of variance and 
applying Tukey’s test. When the data were grouped accord-
ing to age or BMI, multiple comparisons were analyzed using 
two-way analysis of variance and applying Tukey’s test. 
Data was considered statistically different if P,0.05.
ethical considerations
PIVET is accredited with both the self-regulatory national 
Australian authority of the Reproductive Technology 
Accreditation Committee, as well as the statutory Western 
Figure 1 novel dehydroepiandrosterone (Dhea) troches.
Note: Photograph displaying the novel Dhea-containing oral troches designed by 
our group, cross-scored to enable fractional dosages from 12.5 mg to 50 mg.
Figure 2 Patient age and body mass index (BMI) characteristics.
Note: Patients in each cohort either not receiving dehydroepiandrosterone (Dhea) troches (control group; circles) or receiving Dhea troches (treated group; squares) 
had similar age (A) and BMI (B) means and ranges.





Australian state accreditation body of the Reproductive 
Technology Council of Western Australia (established under 
the Western Australian Human Reproductive  Technology 
Act, 1991). These agencies monitor all activities conducted 
at PIVET and demand oversight by a National Health and 
Medical Research Council-constituted institutional ethics 
committee who endorse all clinical and laboratory protocols. 
PIVET laboratories are also accredited with the National 
Australian Testing Authority, which requires strict adher-
ence to quality-assurance protocols. Specific ethics approval 
was not required for this study, as all procedures and blood 
tests were embraced by routine approved clinical protocols. 
Figure 3 Effect of dehydroepiandrosterone (DHEA) troches on serum androgen profile.
Notes: Treatment with DHEA troches increased the serum concentration of a number of androgen-related analytes. Total/free testosterone (A, B), free-androgen index 
(D), DHEA sulfate (E), and androstenedione (F) were all significantly increased. However, sex hormone-binding globulin (SHBG) remained unchanged (C). The control 
cohort did not receive Dhea, and measure 2 was made on average 50±3 weeks (standard error of mean) following the initial androgen-profile screen. Significantly different 
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However, reporting of the data was approved under Curtin 
University Ethics Committee RD_25-10 general approval 
for retrospective data analysis 2015. All participants signed 
written consent forms stating that:
The data will be used for national statistical reporting, regu-
latory review and population based research, and there is no 
publication of information that identifies any individual.
Results
The effect of DHEA troches on serum 
androgen profile
Adjuvant treatment with DHEA troches increased 
serum androgen profile. Total and free testosterone 
(Figure 3A and B) were both significantly increased 
in patients treated with DHEA: from mean values of 
0.68±0.08 nmol/L and 8.2±1.1 pmol/L, respectively, 
to 2.2±0.14 nmol/L and 29.0±3.0 pmol/L, respectively. 
Serum SHBG remained unchanged (Figure 3C), but the 
free-androgen index (FAI) was significantly elevated 
from 1.2±0.18 at baseline to 4.6±0.54 postsupplementa-
tion (Figure 3D). Both DHEAS (Figure 3E) and andros-
tenedione (Figure 3F) were significantly increased: from 
5.7±0.63 μmol/L and 5.9±0.63 nmol/L, respectively, to 
13.7±0.87 μmol/L and 14.7±1.12 nmol/L, respectively, 
after patients used DHEA troches. The comparative control 
group demonstrated a slight reduction in total and free tes-
tosterone, FAI, DHEAS, and androstenedione, but this was 
not statistically significant. No significant change in SHBG 
was observed in this group.
The influence of age on DHEA-induced 
serum androgen profile
When the androgen responses to DHEA were stratified 
according to female age, the increase in serum analyte 
concentration was found to be independent of the age of 
women receiving DHEA troches. As described earlier, 
supplementation caused a statistically significant increase 
in total and free testosterone (Figure 4A and B, respec-
tively), increased DHEAS and androstenedione levels 
(Figure 4C and D, respectively) in comparison with baseline 
measurements, but no significant alteration in SHBG was 
observed (Figure 4E). Interestingly, when the fold change 
between baseline and DHEA-supplemented values were 
calculated for testosterone, DHEAS, and androstenedione 
within each individual age-group, the relative increase in 
serum concentration was similar across all age-groups and 
for each analyte type (Figure 4F). This indicated that the 
troches induced the same fold increase in androgen profile 
regardless of age.
The influence of body mass index on 
DHEA-induced serum androgen profile
When the androgen responses to DHEA were separated 
according to female BMI, the increases in serum analyte 
concentration from DHEA supplementation were found to 
be dependent on BMI. Patients in the 20.1–25.0 kg/m2 BMI 
category displayed a statistically significant increase in 
total and free testosterone (Figure 5A and B, respectively), 
increased DHEAS and androstenedione levels (Figure 5D 
and E, respectively) in comparison with baseline levels, but 
no significant change in SHBG was observed (Figure 5C). 
Those with a BMI between 25.1 and 30.0 kg/m2 exhibited 
the same response, but the elevation in androstenedione 
was not significantly different from the corresponding 
baseline measurement (Figure 5E). Patients in the lowest 
BMI group (,20.0 kg/m2) tended to have lower testosterone 
and DHEAS (Figure 5A, B, and D), but higher SHBG and 
androstenedione (Figure 5C and E) levels in comparison 
with other BMI groups postsupplementation. However, the 
supplement-induced enhancement of free testosterone was 
not significantly different from the corresponding baseline 
measurement (Figure 5B). Most interestingly, patients in the 
highest BMI group (.30.0 kg/m2) also tended to have lower 
androgen responses to DHEA supplementation in comparison 
with other BMI groups. Although there was a trend toward 
increased levels of testosterone (Figure 5A and B), DHEAS 
(Figure 5D), and androstenedione (Figure 5E) after admin-
istration of DHEA troches, the increase was not statistically 
different from the corresponding baseline level.
Discussion
DHEA supplementation is now widely used by more than 
25% of IVF clinicians worldwide for poor-responding 
patients with diminished ovarian reserve, yet the true benefit 
of this adjuvant therapy remains unknown.19 In addition, 
most original clinical articles and meta-analyses discussing 
the application of DHEA therapy in IVF have failed to report 
the impact of supplementation on the level of related serum 
androgens in the bloodstream, with the notable exception of 
Zhang et al.31 In the current study, we attempted to address 
this issue and demonstrate that the use of novel DHEA-
containing oral troches could enhance the serum androgen 
profile significantly in patients undergoing IVF.
We demonstrated that sublingual DHEA administration 
(50 mg daily) increased free testosterone, total testosterone, 





androstenedione, and DHEAS levels in a highly significant 
manner (P,0.0001). No change in SHBG was detected, but 
the largest rise was observed in FAI, with a 3.8-fold increase. 
This was followed by an increase in free and total testoster-
one (3.5-fold and 3.3-fold, respectively), and then andros-
tenedione (2.5-fold) and DHEAS (2.5-fold). These data are 
comparable to other reports showing that oral administration 
of DHEA (50 mg daily) in older women (40–70 years old) 
increased the levels of androstenedione and total testosterone 
by approximately twofold, which is of a similar magnitude to 
those observed in our current study.32 Conversely, in another 
study, the increment of androstenedione and total testosterone 
levels in menopausal female patients (60–70 years old) 
following topical administration of DHEA (2 g/daily) was 
Figure 4 Influence of age on dehydroepiandrosterone (DHEA)-induced serum androgen profile.
Notes: The increase in serum analyte concentration was found to be independent of the age of women receiving DHEA troches. Supplementation caused a statistically 
significant increase in total and free testosterone (A and B, respectively), increased DHEA sulfate (DHEAS) and androstenedione levels (C and D, respectively), but no 
significant alteration in sex hormone-binding globulin (SHBG) was observed (E). When the fold change between baseline and DHEA-supplemented values were calculated 
for testosterone, DHEAS, and androstenedione for each of the individual age-groups, the relative increase in serum concentration was not significantly different with regard 
to age or analyte type (F). *Significantly different from baseline measurements of patients aged ,35 years (P,0.05); #significantly different from baseline measurements of 
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twofold and 1.5-fold, respectively, which was significantly 
lower than that shown in our current study.33 Furthermore, 
we found that DHEAS was increased by approximately 
2.5-fold using oral troches, while DHEAS was increased 
by a similar 2.3-fold in this previous percutaneous study.33 
More recently, Zhang et al demonstrated that DHEA supple-
mentation in patients with poor ovarian response for three 
IVF cycles (about 3 months) increased DHEAS and total 
Figure 5 Impact of body mass index (BMI) and dehydroepiandrosterone (DHEA) on serum androgen profile.
Notes: DHEA increased serum androgen content in a BMI-dependent manner. Patients in the middle BMI categories displayed a significant increase in total and free 
testosterone (A and B, respectively) and increased DHEA sulfate (DHEAS) and androstenedione levels (D and E, respectively). No significant change in sex hormone-binding 
globulin (SHBG) was observed (C). Lower-BMI patients (,20.0 kg/m2) tended to have lower testosterone and Dheas (A, B, D), but higher SHBG and androstenedione 
(C and E) levels in comparison with other BMI groups postsupplementation. Those in the highest-BMI group (.30.0 kg/m2) also tended to have lower androgen responses 
to DHEA supplementation in comparison with other BMI groups. Although there was a trend toward increased levels of testosterone (A and B), Dheas (D), and 
androstenedione (E) after administration of DHEA troches, the increase was not statistically different from the corresponding baseline levels. The fold change for each 
androgen in each BMI group is shown in (F). *Significantly different from baseline measurements of patients ,20.0 kg/m2 (P,0.05); #significantly different from baseline 
measurements of patients 20.1–25.0 kg/m2 (P,0.05); θsignificantly different from baseline measurements of patients 25.1–30.0 kg/m2 (P,0.05); &significantly different from 
DHEA measurements of patients .30.0 kg/m2 (P,0.05); Ψsignificantly different from patients with DHEA and BMI of 25.1–30.0 kg/m2 (P,0.05).
testosterone by 4.4-fold and threefold, respectively.31 While 
their DHEAS response was greater than the current study, 
we did demonstrate a comparable total testosterone response 
with very similar baseline and posttreatment testosterone 
levels.31 Interestingly, this group supplemented IVF patients 
with more DHEA (75 mg daily) and for a longer time frame 
(three cycles) in comparison to our 50 mg DHEA daily 
supplementation over 4 weeks, and the former study did not 





reveal how the agent was administered (orally, percutane-
ously, etc).31 Taken together, these data reveal that applica-
tion of our novel oral troches with a lower concentration of 
DHEA caused a similar increase in DHEAS levels to previous 
studies utilizing oral DHEA treatments or topical ointments 
to bypass first-pass metabolism. However, the amount of 
serum androstenedione and testosterone using our oral troche 
formulation was greater than these previous studies, indicat-
ing a more efficient therapeutic intervention.
It is clear that androgen levels, particularly DHEA/
DHEAS, decrease with advancing age10 by approximately 
10% per decade until approximately 80 years of age.2,34,35 
Interestingly, we found that individual age had no signifi-
cant influence on baseline serum analyte concentration. All 
patients in each age category (,35, 35–39 and $40 years) 
had similar total and free testosterone, androstenedione, and 
SHBG concentrations. However, there was a decreasing trend 
in DHEAS level noted for patients 35 years and above, but 
this was not significantly different from the average DHEAS 
level for individuals below 35 years. It is likely that the cur-
rent study would not detect a significant change in baseline 
DHEAS levels, as the patient cohort was relatively young, 
with the oldest patient aged 45 years, and limited to 31 par-
ticipants. Nonetheless, in our cohort, we found that patient age 
did not influence serum androgen profile following DHEA-
supplementation. When patient responses were stratified 
according to age, the fold increase in serum concentration was 
similar for all measured analytes and across all age-groups. 
This indicated that age did not affect the efficiency of the 
oral troche treatment.
The relationship between BMI and serum DHEA is 
unclear, as several conflicting reports have been published.36–39 
However, from the current study, we have added further 
evidence to demonstrate that BMI plays a significant role 
in DHEA and androgen metabolism, but only following 
supplementation, as no statistically significant difference in 
hormone levels was detected at baseline measurements when 
female patients were grouped according to BMI, similar to 
previous studies.36,40 However, after DHEA treatment, gener-
ally individuals with a lower BMI displayed an attenuated 
rise in DHEAS and testosterone levels, but a higher andros-
tenedione response. The impact on DHEAS and testosterone 
may have been a consequence of higher serum SHBG levels 
found in these patients. Overall, the best responders tended to 
be patients in the 25.1–30.0 kg/m2 BMI category. However, 
there was a marked reduction in DHEAS, androstenedione, 
and testosterone responses postsupplementation for obese 
patients (.30.0 kg/m2). Our results describe increases after 
DHEA treatment, but the results were not statistically differ-
ent from the corresponding baseline values. This implied that 
patients of excessive body weight either required a greater 
dose of DHEA to achieve a statistically significant increase 
in serum hormones from baseline (perhaps due to greater 
circulatory volume), or that the administered dose may have 
been biologically diluted within the larger volume of adipose 
tissue, or finally that there may have been a higher metabolic 
aromatization of androgens to estrogens, which is expected 
in obese individuals with higher fat mass and aromatase 
activity.41,42 Experiments to elucidate these hypotheses are 
currently under way in the authors’ laboratory.
This study has demonstrated the impact of our sublin-
gual DHEA troches on serum androgen profile in patients 
undertaking IVF programs. This method of DHEA admin-
istration attains similar degrees of testosterone, DHEAS, 
and androstenedione enhancement in comparison with 
other techniques.31–33 More importantly, we have shown 
that BMI significantly influences DHEA uptake and 
metabolism, and these data suggested that BMI should be 
carefully considered during dosage calculation to ensure 
a significant and robust androgen-profile boost in patients 
undergoing IVF.
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